90 related articles for article (PubMed ID: 1152158)
1. Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis.
Prout GR; Irwin RJ; Kliman B; Daly JJ; MacLaughlin RA; Griffin PP
J Urol; 1975 Jun; 113(6):834-40. PubMed ID: 1152158
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].
Aso Y; Akaza H; Koiso K; Kameyama S; Koyanagi T; Kawai T; Kumamoto Y; Tazaki H; Funyu T; Oshima H
Hinyokika Kiyo; 1993 Apr; 39(4):391-403. PubMed ID: 8503339
[TBL] [Abstract][Full Text] [Related]
3. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study.
Lund F; Rasmussen F
Br J Urol; 1988 Feb; 61(2):140-2. PubMed ID: 3280080
[TBL] [Abstract][Full Text] [Related]
4. A new antiprostatic agent for treatment of prostatic carcinoma.
Irwin RJ; Prout GR
Surg Forum; 1973; 24():536-7. PubMed ID: 4806089
[No Abstract] [Full Text] [Related]
5. Short term effects of flutamide administration on hypothalamic-pituitary-testicular axis in man.
Migliari R; Balzano S; Scarpa RM; Campus G; Pintus C; Usai E
J Urol; 1988 Mar; 139(3):637-9. PubMed ID: 3125348
[TBL] [Abstract][Full Text] [Related]
6. Flutamide therapy for advanced prostatic cancer: a phase II study.
MacFarlane JR; Tolley DA
Br J Urol; 1985 Apr; 57(2):172-4. PubMed ID: 3986452
[TBL] [Abstract][Full Text] [Related]
7. [Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer].
Aso Y; Akaza H; Koiso K; Kumamoto Y; Kawai T; Origasa S; Hosaka M; Yamanaka H; Shimazaki J; Fuse H
Hinyokika Kiyo; 1993 Apr; 39(4):381-9. PubMed ID: 8503338
[TBL] [Abstract][Full Text] [Related]
8. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
9. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer.
Jacobo E; Schmidt JD; Weinstein SH; Flocks RH
Urology; 1976 Sep; 8(3):231-3. PubMed ID: 788293
[TBL] [Abstract][Full Text] [Related]
10. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
Labrie F; Dupont A; Belanger A; Lachance R
J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
Akaza H; Usami M; Kotake T; Koiso K; Aso Y
Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
Pavone-Macaluso M; Serretta V; Daricello G; Pavone C; Cacciatore M; Romano C; Cavallo N
Prog Clin Biol Res; 1990; 350():149-57. PubMed ID: 2201041
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic resistance to luteinizing hormone-releasing hormone analogue in a patient with prostatic carcinoma.
Jorion JL
J Urol; 1992 Nov; 148(5):1539-40. PubMed ID: 1279215
[No Abstract] [Full Text] [Related]
14. The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins.
Hellman L; Bradlow HL; Freed S; Levin J; Rosenfeld RS; Whitmore WF; Zumoff B
J Clin Endocrinol Metab; 1977 Dec; 45(6):1224-9. PubMed ID: 591617
[TBL] [Abstract][Full Text] [Related]
15. The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study.
Caine M; Perlberg S; Gordon R
J Urol; 1975 Oct; 114(4):564-8. PubMed ID: 66331
[TBL] [Abstract][Full Text] [Related]
16. Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary-gonadal axis.
Prout GR; Kliman B; Daly JJ; MacLaughlin RA; Griffin PP; Young HH
Urology; 1976 Feb; 7(2):148-55. PubMed ID: 1246784
[TBL] [Abstract][Full Text] [Related]
17. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
[TBL] [Abstract][Full Text] [Related]
19. Flutamide as primary treatment for metastatic prostatic cancer.
Lundgren R
Br J Urol; 1987 Feb; 59(2):156-8. PubMed ID: 3828712
[TBL] [Abstract][Full Text] [Related]
20. Long-term experience with flutamide in patients with prostatic carcinoma.
Prout GR; Keating MA; Griffin PP; Schiff SF
Urology; 1989 Oct; 34(4 Suppl):37-45; discussion 46-56. PubMed ID: 2800092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
